APOA1 and liver cancer: We found that serum ApoA-1 level was significantly associated with TTR and OS for the variables as follows: AFP ≤ 400 ng/mL for TTR (median 13.4 months vs. not reached, p=0.002, Figure 2A), Barcelona Clinic Liver Cancer (BCLC) stages 0+A for TTR (median 13.5 months vs. not reached, p<0.001, Figure 2B), AFP ≤ 400 ng/mL for OS (p=0.014, Figure 2C), BCLC 0+A for OS (p=0.042, Figure 2D).